Skip to main content
x

New Product Announcement Background
New Product Announcement Background

OUR FIRST TREATMENT
IS AVAILABLE

myNEURELIS
myNeurelis Background

SUPPORTING PATIENTS
THROUGH TREATMENT

Our-Pipeline-Slide
slide-2

Passionate About
Helping Patients

Our Technology Slide
slide-4

EXPLORE OUR
INNOVATIVE TECHNOLOGIES

Neurelis-News-slide
slide-3

NEURELIS IS
MAKING HEADLINES

Partner-With-Us-Slide
slide-4

HELP US
Help Patients

WE'RE COMMITTED TO YOU

VIEW MESSAGE FROM NEURELIS, INC., PRESIDENT AND CHIEF EXECUTIVE OFFICER ABOUT THE COVID-19 PANDEMIC

OUR PASSION IS PROGRESS

Neurelis is an innovation-driven neuroscience company that provides a differentiated approach to target unmet medical needs. Our application of novel technologies is designed to enhance therapeutic benefit and patient care.

OUR PRODUCT

We have reached a milestone in patient care with the first FDA-approved treatment from Neurelis.

OUR SAVINGS AND SUPPORT PROGRAM

We want to ensure that patients using our innovative therapies get the support and savings they need to stay on treatment.

OUR PIPELINE

Our pipeline currently includes several investigational product candidates at various stages of development.

OUR TECHNOLOGIES

Neurelis has a proprietary technology portfolio that includes Intravail®, ProTek®, and Hydrogel™ for drug delivery enhancement. These three non-invasive drug delivery and stabilization technologies are applicable to a wide range of molecules, including therapeutic proteins, peptides, and non-peptide large and small molecules. Our technologies offer exceptional potential value in enhancing drug development and clinical performance.

ABOUT NEURELIS

Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.

KEEP CURRENT

Get the most up-to-date information about Neurelis and our products.

HAVE A QUESTION ABOUT NEURELIS?

Please contact us if you have any questions about Neurelis or any of the products we are currently developing. 

Contact Us